{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34716349",
  "DateCompleted": {
    "Year": "2021",
    "Month": "11",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "12",
    "Day": "14"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "10",
        "Day": "29"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "6238",
      "10.1038/s41467-021-26557-5"
    ],
    "Journal": {
      "ISSN": "2041-1723",
      "JournalIssue": {
        "Volume": "12",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Oct",
          "Day": "29"
        }
      },
      "Title": "Nature communications",
      "ISOAbbreviation": "Nat Commun"
    },
    "ArticleTitle": "Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa.",
    "Pagination": {
      "StartPage": "6238",
      "MedlinePgn": "6238"
    },
    "Abstract": {
      "AbstractText": [
        "Low- and middle-income countries are implementing COVID-19 vaccination strategies in light of varying vaccine efficacies and costs, supply shortages, and resource constraints. Here, we use a microsimulation model to evaluate clinical outcomes and cost-effectiveness of a COVID-19 vaccination program in South Africa. We varied vaccination coverage, pace, acceptance, effectiveness, and cost as well as epidemic dynamics. Providing vaccines to at least 40% of the population and prioritizing vaccine rollout prevented >9 million infections and >73,000 deaths and reduced costs due to fewer hospitalizations. Model results were most sensitive to assumptions about epidemic growth and prevalence of prior immunity to SARS-CoV-2, though the vaccination program still provided high value and decreased both deaths and health care costs across a wide range of assumptions. Vaccination program implementation factors, including prompt procurement, distribution, and rollout, are likely more influential than characteristics of the vaccine itself in maximizing public health benefits and economic efficiency."
      ],
      "CopyrightInformation": "\u00a9 2021. The Author(s)."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-1832-2193"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA. kpreddy@mgh.harvard.edu."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA. kpreddy@mgh.harvard.edu."
          },
          {
            "Identifier": [],
            "Affiliation": "Harvard Medical School, Boston, MA, USA. kpreddy@mgh.harvard.edu."
          }
        ],
        "LastName": "Reddy",
        "ForeName": "Krishna P",
        "Initials": "KP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA."
          }
        ],
        "LastName": "Fitzmaurice",
        "ForeName": "Kieran P",
        "Initials": "KP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA."
          }
        ],
        "LastName": "Scott",
        "ForeName": "Justine A",
        "Initials": "JA"
      },
      {
        "Identifier": [
          "0000-0001-6604-491X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Africa Health Research Institute, KwaZulu-Natal, South Africa."
          },
          {
            "Identifier": [],
            "Affiliation": "MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa."
          },
          {
            "Identifier": [],
            "Affiliation": "School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, KwaZulu-Natal, South Africa."
          },
          {
            "Identifier": [],
            "Affiliation": "Institute for Global Health, University College London, London, UK."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Epidemiology and Harvard Center for Population and Development Studies, Harvard T.H. Chan School of Public Health, Boston, MA, USA."
          }
        ],
        "LastName": "Harling",
        "ForeName": "Guy",
        "Initials": "G"
      },
      {
        "Identifier": [
          "0000-0003-0926-710X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "KwaZulu-Natal Research Innovation and Sequencing (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa."
          }
        ],
        "LastName": "Lessells",
        "ForeName": "Richard J",
        "Initials": "RJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA."
          }
        ],
        "LastName": "Panella",
        "ForeName": "Christopher",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Harvard Medical School, Boston, MA, USA."
          }
        ],
        "LastName": "Shebl",
        "ForeName": "Fatma M",
        "Initials": "FM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Harvard Medical School, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA."
          }
        ],
        "LastName": "Freedberg",
        "ForeName": "Kenneth A",
        "Initials": "KA"
      },
      {
        "Identifier": [
          "0000-0003-3506-842X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Harvard Medical School, Boston, MA, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Africa Health Research Institute, KwaZulu-Natal, South Africa."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA."
          }
        ],
        "LastName": "Siedner",
        "ForeName": "Mark J",
        "Initials": "MJ"
      }
    ],
    "GrantList": [
      {
        "GrantID": "210479/Z/18/Z",
        "Agency": "Wellcome Trust (Wellcome)",
        "Country": ""
      },
      {
        "GrantID": "R37 AI058736-16S1",
        "Agency": "U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)",
        "Country": ""
      },
      {
        "GrantID": "210479/Z/18/Z",
        "Acronym": "WT_",
        "Agency": "Wellcome Trust",
        "Country": "United Kingdom"
      },
      {
        "Acronym": "WT_",
        "Agency": "Wellcome Trust",
        "Country": "United Kingdom"
      },
      {
        "GrantID": "R37 AI058736",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nat Commun",
    "NlmUniqueID": "101528555",
    "ISSNLinking": "2041-1723"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "medRxiv. 2021 May 12;:",
      "PMID": "34013291"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "immunology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Cost-Benefit Analysis"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Hospitalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "South Africa"
    }
  ],
  "CoiStatement": "R.J.L. serves on South Africa\u2019s Ministerial Advisory Committee on COVID-19 Vaccines (VMAC). The authors declare no additional competing interests."
}